1 |
Al Muderis M, Azzopardi T, Cundy P. Zebra lines of pamidronate therapy in children. J Bone Joint Surg Am 2007;89:1511-6.
DOI
|
2 |
Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003;33:226-9.
DOI
|
3 |
Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004;19:1191-3.
DOI
|
4 |
Suresh S, Thomas JK. Metaphyseal bands in osteogenesis imperfect. Indian J Radiol Imaging 2010;20:42-4.
DOI
|
5 |
Hong IK, Suh JS, Lee YA, Kim DY. Scintigraphic findings of growth arrest lines after bisphosphonate administration in a steroid-induced osteoporosis patient: a case study. Clin Nucl Med 2010;35:740-2.
DOI
|
6 |
Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 1994;94:385-9.
|
7 |
Ogden JA. Growth slowdown and arrest lines. J Pediatr Orthop 1984;4:409-15.
DOI
|
8 |
Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76:266-83.
DOI
ScienceOn
|
9 |
Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 1998;157:261-2.
|
10 |
Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001;14:529-33.
|
11 |
Sumnik Z, Land C, Rieger-Wettengi G, Korber F, Strabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res 2004;61:137-42.
DOI
|
12 |
Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 2008;21:811-8.
|
13 |
Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
DOI
ScienceOn
|
14 |
Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005;18:43-53.
|
15 |
Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, et al. International Society for Clinical Densitometry: Official positions of the International Society for Clinical Densitometry. J Clin endocrinol Metab 2004;89:3651-5.
DOI
ScienceOn
|
16 |
Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta-- lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002;15:163-74.
|
17 |
Silverman SL, Hurvitz EA, Nelson VS, Chiodo A. Rachitic syndrome after disodium etidronate therapy in an adolescent. Arch Phys Med Rehabil 1994;75:118-20.
|
18 |
Onwuneme C, Abdalla K, Cassidy N, Hensey O, Ryan S. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis. Arch Dis Child 2007;92:1087.
DOI
|
19 |
Devogelaer JP, Malghem J, Maldaque B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;16:360-3.
DOI
ScienceOn
|
20 |
Kim SD, Cho BS. Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 2006;102:c81-7.
DOI
ScienceOn
|